|
PULSE Registry: for Patients Receiving Lutetium (177Lu) Vipivotide Tetraxetan
RECRUITINGSponsored by Novartis Pharmaceuticals
Actively Recruiting
SponsorNovartis Pharmaceuticals
Started2026-09-30
Est. completion2031-07-31
Eligibility
SexMALE
Healthy vol.Accepted
View on ClinicalTrials.gov →
NCT07484269
Summary
The primary objective of the study is to describe real-world drug utilisation of lutetium (177Lu) vipivotide tetraxetan among patients with metastatic prostate cancer
Eligibility
Sex: MALEHealthy volunteers accepted
Inclusion criteria: Age ≥ 18 years at index date * Diagnosis of mPC * PSMA positive * Received at least one dose of lutetium (177Lu) vipivotide tetraxetan on or after mPC diagnosis date Exclusion criterion: • Current or prior participation in an investigational study within the 30-day period immediately prior to and including the index date, or within five half-lives of the investigational product (whichever is longer)
Conditions2
CancerMetastatic Prostate Cancer
Browse More Trials
Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.
This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.
Actively Recruiting
SponsorNovartis Pharmaceuticals
Started2026-09-30
Est. completion2031-07-31
Eligibility
SexMALE
Healthy vol.Accepted
View on ClinicalTrials.gov →
NCT07484269